Quick Takeaways
- Clearline Capital LP filed SCHEDULE 13G for TherapeuticsMD, Inc. Common Stock, par value $0.001 per share (TXMD).
- Disclosed ownership: 5.5%.
- Date of event: 31 Dec 2024.
Clearline Capital LP - 31 Dec 2024 SCHEDULE 13G Report for TherapeuticsMD, Inc. Common Stock, par value $0.001 per share (TXMD)
- Filing Manager
- Clearline Capital LP
- Reporting Manager
- Clearline Capital LP
- Symbol
- TXMD
- Shares outstanding
- 11,549,491 shares
- Disclosed Ownership
- 635,222 shares
- Ownership
- 5.5%
- Form type
- SCHEDULE 13G
- Filing time
- 12 Feb 2025, 16:25:45 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Clearline Capital LP disclosed 5.5% ownership in TherapeuticsMD, Inc. Common Stock, par value $0.001 per share (TXMD) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 12 Feb 2025, 16:25.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Clearline Capital LP | 5.5% | 635,222 | 0 | 635,222 | Marc Majzner | Limited Partner | |
| Clearline Capital, LLC | 5.5% | 635,222 | 0 | 635,222 | Marc Majzner | Managing Member | |
| Marc Majzner | 5.5% | 635,222 | 0 | 635,222 | Marc Majzner | Authorized Signatory |